Drug name - Farxiga

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(1 year, 11 months ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(1 year, 11 months ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN103319445B ASTRAZENECA AB Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof
Jun, 2027

(4 years from now)

CN101479287A ASTRAZENECA AB Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773B ASTRAZENECA AB Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid
Jun, 2027

(4 years from now)

CN101479287B ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773A ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445A ASTRAZENECA AB Sglt2 Inhibitor Crystal Structure And Its Preparation Method
Jun, 2027

(4 years from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(1 year, 11 months ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(1 year, 11 months ago)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(1 year, 11 months ago)

EP3045466A1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374B1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374A1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3045466B1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807A1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP3363807B1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP2069374B2 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device Jun, 2025

(2 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes Aug, 2026

(3 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Aug, 2028

(5 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder Jan, 2030

(7 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof May, 2030

(7 years from now)

US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction Mar, 2040

(17 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing hba1c in a human in need thereof in combination with a sustained-release composition containing exendin-4; treatment of type 2 diabetes mellitus in combination with exenatide; reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4; Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone; Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.